Literature DB >> 25957281

Calcium negatively regulates meprin β activity and attenuates substrate cleavage.

Philipp Arnold1, Frederike Schmidt2, Johannes Prox2, Friederike Zunke2, Claus Pietrzik2, Ralph Lucius2, Christoph Becker-Pauly2.   

Abstract

The meprin β metalloproteinase is an important enzyme in extracellular matrix turnover, inflammation, and neurodegeneration in humans and mice. Previous studies showed a diminished cleavage of certain meprin β substrates in the presence of calcium, although the mechanism was not clear. With the help of a specific fluorogenic peptide assay and the human amyloid precursor protein as substrate, we demonstrated that the influence of calcium is most likely a direct effect on human meprin β itself. Analyzing the crystal structures of pro- and mature meprin β helped to identify a cluster of negatively charged amino acids forming a potential calcium binding site. Mutation of 2 of these residues (D204A and D245A) led to severe differences in proteolytic activity and cellular localization of meprin β. D245A was almost completely inactive and largely stored into intracellular vesicles, indicating severe misfolding of the protein. Astonishingly, D204A was not transported to the cell surface, but exhibited strong β-secretase activity, resulting in massive accumulation of Aβ-peptides. This could be explained by constitutive maturation of this meprin β mutant already in the early secretory pathway. We hypothesize that lacking D204 abrogates the capability of binding calcium in the catalytic domain, an important step for proper folding of the propeptide and subsequent inhibition of the protease. This is supported by the inhibition constant of calcium for meprin β (inhibitory constant 50 = 11 mM), which resembles the physiologic concentrations found in the endoplasmic reticulum. For instance, it was shown for amyotrophic lateral sclerosis that a loss of calcium in the endoplasmic reticulum leads to the misfolding of calcium-dependent proteins, which might also be relevant for proper function of meprin β. © FASEB.

Entities:  

Keywords:  APP; amyloid β; protease; protein folding

Mesh:

Substances:

Year:  2015        PMID: 25957281     DOI: 10.1096/fj.15-272310

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  6 in total

Review 1.  Proteolytic ectodomain shedding of membrane proteins in mammals-hardware, concepts, and recent developments.

Authors:  Stefan F Lichtenthaler; Marius K Lemberg; Regina Fluhrer
Journal:  EMBO J       Date:  2018-07-05       Impact factor: 11.598

2.  Generation of aggregation prone N-terminally truncated amyloid β peptides by meprin β depends on the sequence specificity at the cleavage site.

Authors:  Caroline Schönherr; Jessica Bien; Simone Isbert; Rielana Wichert; Johannes Prox; Hermann Altmeppen; Sathish Kumar; Jochen Walter; Stefan F Lichtenthaler; Sascha Weggen; Markus Glatzel; Christoph Becker-Pauly; Claus U Pietrzik
Journal:  Mol Neurodegener       Date:  2016-02-19       Impact factor: 14.195

Review 3.  The Metalloprotease Meprin β Is an Alternative β-Secretase of APP.

Authors:  Christoph Becker-Pauly; Claus U Pietrzik
Journal:  Front Mol Neurosci       Date:  2017-01-05       Impact factor: 5.639

4.  Joint Reconstituted Signaling of the IL-6 Receptor via Extracellular Vesicles.

Authors:  Philipp Arnold; Wiebke Lückstädt; Wenjia Li; Inga Boll; Juliane Lokau; Christoph Garbers; Ralph Lucius; Stefan Rose-John; Christoph Becker-Pauly
Journal:  Cells       Date:  2020-05-24       Impact factor: 6.600

5.  Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia.

Authors:  Marvin Heimke; Florian Lenz; Uta Rickert; Ralph Lucius; François Cossais
Journal:  Cells       Date:  2022-10-02       Impact factor: 7.666

6.  Aldosterone exerts anti-inflammatory effects on LPS stimulated microglia.

Authors:  Björn-Ole Bast; Uta Rickert; Janna Schneppenheim; François Cossais; Henrik Wilms; Philipp Arnold; Ralph Lucius
Journal:  Heliyon       Date:  2018-10-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.